Search
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalBy blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.
Lurbinectedin
go.drugbank.com/drugs/DB12674ApprovedInvestigationalthe substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. … [L14336] This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials
Oteracil
go.drugbank.com/drugs/DB03209ApprovedInvestigationalApproved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno". … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells.
Tolazamide
go.drugbank.com/drugs/DB00839ApprovedA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Synonyms: N-(p-Toluenesulfonyl)-N'-hexamethyleniminoureaCategories: Drugs Used in DiabetesRiluzole
go.drugbank.com/drugs/DB00740ApprovedInvestigationalA glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis.
Categories: Compounds used in a research, industrial, or household settingNitazoxanide
go.drugbank.com/drugs/DB00507ApprovedInvestigationalVet approvedThis drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. … Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment
Products: N/aAngiotensin II
go.drugbank.com/drugs/DB11842ApprovedInvestigationalAs distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment … The novelty of the medication lies in the fact that it is the first and only use of synthetic human angiotensin II to help maintain body blood pressure.
Nipocalimab
go.drugbank.com/drugs/DB16257ApprovedInvestigational[L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis. … [L64042] This reduction in autoantibodies underlies its therapeutic effect across autoantibody-driven conditions.[L64042] It is administered by intravenous infusion.
Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigationalIn June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023. … [A260122,A260127] Other kinases have a cysteine at a position equivalent to Cys-909 in JAK3, and several of them belong to the TEC kinase family.
Ioxilan
go.drugbank.com/drugs/DB09135ApprovedWithdrawnIntravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant
Categories: Compounds used in a research, industrial, or household settingSynonyms: N-(2,3-dihydroxypropyl)-N’-(2- hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide